Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free RPRX Stock Alerts

Royalty Pharma (RPRX) Short Interest Ratio & Short Volume

Royalty Pharma logo
$63.31 +0.20 (+0.32%)
As of 12:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Royalty Pharma Short Interest Overview

As of August 14, 2026, Royalty Pharma (RPRX) had a short interest of 11.61 million shares sold short, representing 2.49% of the public float. This marks a 8.80% increase in short interest since the prior report. The short interest ratio (days to cover) is 3.8, meaning it would take 3.8 days of the average trading volume of 3.44 million shares to cover all short positions.

Current Short Interest
11,606,728 shares
Previous Short Interest
10,667,818 shares
Change Vs. Previous Month
8.80%
Dollar Volume Sold Short
$680.15 million
Short Interest Ratio
3.8 Days to Cover
Last Record Date
August 14, 2026
Outstanding Shares
575,000,000 shares
Short Percent of Float
2.49%
Today's Trading Volume
775,404 shares
Average Trading Volume
3,441,387 shares
Today's Volume Vs. Average
23%
Short Selling Royalty Pharma?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Royalty Pharma and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

RPRX Short Interest Over Time

RPRX Days to Cover Over Time

RPRX Percentage of Float Shorted Over Time

Royalty Pharma Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/14/202611,606,728 shares $680.15 million +8.8%2.5%3.77 $58.60
7/31/202610,667,818 shares $623.32 million -12.1%2.3%4.07 $58.43
7/15/202612,134,646 shares $683.30 million -2.5%2.6%4.44 $56.31
6/30/202612,443,449 shares $697.70 million +11.8%2.7%2.98 $56.07
6/15/202611,133,208 shares $604.20 million -3.9%2.4%3.04 $54.27
5/29/202611,588,307 shares $646.16 million -8.6%2.5%2.47 $55.76
5/15/202612,683,834 shares $670.34 million -8.2%2.7%3.32 $52.85
4/30/202613,816,927 shares $692.09 million +15.0%3.0%4.41 $50.09
4/15/202612,011,065 shares $584.94 million +4.3%2.6%4.36 $48.70
3/31/202611,520,329 shares $552.63 million -0.5%2.5%3.31 $47.97
3/13/202611,579,085 shares $528.59 million -4.8%2.5%3.44 $45.65
2/27/202612,161,157 shares $561.97 million -9.5%2.6%4.27 $46.21
2/13/202613,443,797 shares $607.53 million -49.2%2.9%3.03 $45.19
1/30/202626,462,455 shares $1.10 billion -3.8%5.7%7.2 $41.68
1/15/202627,513,663 shares $1.09 billion -4.5%5.9%6.96 $39.72
12/31/202528,800,189 shares $1.11 billion +3.9%6.2%9.29 $38.64
12/15/202527,721,192 shares $1.07 billion +13.9%5.9%5.45 $38.53
11/28/202524,331,177 shares $977.51 million +1.3%5.2%6.48 $40.18
11/14/202524,029,541 shares $941.00 million +69.3%5.1%4.49 $39.16
10/31/202514,193,421 shares $532.82 million +4.6%3.0%6.15 $37.54
10/15/202513,580,000 shares $491.32 million +5.5%4.0%3.6 $36.18
9/30/202512,870,000 shares $454.05 million -39.5%3.8%3.4 $35.28
9/15/202521,280,000 shares $747.99 million +28.0%6.3%5.3 $35.15
8/31/202516,620,000 shares $597.99 million +18.1%4.9%4.5 $35.98
8/15/202514,070,000 shares $511.44 million -7.3%4.1%3.8 $36.35
7/31/202515,180,000 shares $558.62 million -9.3%4.6%3.5 $36.80
7/15/202516,730,000 shares $610.81 million -1.1%5.0%3.7 $36.51
6/30/202516,910,000 shares $609.27 million -41.8%5.1%3.5 $36.03
6/15/202529,030,000 shares $1.01 billion +0.0%8.7%5.6 $34.84
5/31/202529,020,000 shares $959.40 million +39.9%8.7%5.9 $33.06
5/15/202520,740,000 shares $686.91 million +11.6%6.2%4.3 $33.12
4/30/202518,590,000 shares $610.12 million -9.6%5.4%4 $32.82
4/15/202520,570,000 shares $667.50 million +14.2%6.2%4.5 $32.45
3/31/202518,010,000 shares $560.65 million +15.7%5.4%3.8 $31.13
3/15/202515,570,000 shares $510.23 million +13.2%4.7%3.7 $32.77
2/28/202513,750,000 shares $462.55 million -10.1%4.1%3.3 $33.64
2/15/202515,300,000 shares $495.11 million -5.2%4.1%3.9 $32.36
1/31/202516,130,000 shares $509.39 million -3.0%4.2%4.3 $31.58
1/15/202516,630,000 shares $511.21 million +0.4%4.4%5 $30.74
12/31/202416,560,000 shares $422.45 million +5.8%4.4%5.8 $25.51
The $15 Gold Fund That Pays Up to $1,152/Month (Ad)

Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel

Discover the gold income fund before the next payout date
12/15/202415,650,000 shares $388.75 million -0.3%4.1%5.8 $24.84
11/30/202415,700,000 shares $418.56 million +7.0%4.1%6.4 $26.66
11/15/202414,670,000 shares $377.02 million +0.8%3.9%6.1 $25.70
10/31/202414,550,000 shares $392.85 million +0.6%3.8%6.5 $27.00
10/15/202414,460,000 shares $402.57 million -0.8%3.8%6 $27.84
9/30/202414,570,000 shares $412.19 million +2.7%3.8%5.9 $28.29
9/15/202414,190,000 shares $393.35 million -3.3%3.7%5.4 $27.72
8/31/202414,680,000 shares $426.16 million +2.8%3.8%5.5 $29.03
8/15/202414,280,000 shares $391.41 million -4.0%3.7%5 $27.41
7/31/202414,870,000 shares $418.89 million -9.8%3.9%5.4 $28.17
7/15/202416,490,000 shares $439.46 million -2.4%4.3%6.1 $26.65
6/30/202416,900,000 shares $445.65 million +8.8%4.4%6.1 $26.37
6/15/202415,540,000 shares $418.34 million +17.3%4.1%5.8 $26.92
5/31/202413,250,000 shares $363.18 million -0.2%3.5%4.9 $27.41
5/15/202413,280,000 shares $374.63 million -3.4%3.5%5.1 $28.21
4/30/202413,750,000 shares $380.88 million -2.8%3.6%4.8 $27.70
4/15/202414,150,000 shares $399.74 million +14.2%3.7%5.2 $28.25
3/31/202412,390,000 shares $376.28 million -2.1%3.3%4.7 $30.37
3/15/202412,650,000 shares $380.64 million -3.7%3.3%4.9 $30.09
2/29/202413,130,000 shares $398.36 million +14.2%3.5%4.8 $30.34
2/15/202411,500,000 shares $345.35 million +11.9%3.0%4.1 $30.03
1/31/202410,280,000 shares $291.85 million +0.9%2.7%4.1 $28.39
1/15/202410,190,000 shares $289.19 million -9.1%2.7%4.3 $28.38
12/31/202311,210,000 shares $314.89 million -9.2%2.9%4.8 $28.09
12/15/202312,340,000 shares $337.75 million +23.3%3.2%5.3 $27.37
11/30/202310,010,000 shares $270.97 million +1.8%2.6%4.3 $27.07
11/15/20239,830,000 shares $265.61 million -10.4%2.6%4.5 $27.02
10/31/202310,970,000 shares $294.76 million -2.8%2.9%5 $26.87
10/15/202311,290,000 shares $314.31 million +8.0%3.0%5.2 $27.84
9/30/202310,450,000 shares $283.61 million +11.7%2.8%4.8 $27.14
9/15/20239,360,000 shares $263.30 million +9.5%2.5%4.3 $28.13
8/31/20238,550,000 shares $254.96 million -8.7%2.3%3.7 $29.82
8/15/20239,360,000 shares $278.93 million +0.2%2.5%3.9 $29.80
7/31/20239,340,000 shares $293.09 million -14.2%2.5%3.9 $31.38
7/15/202310,890,000 shares $334.65 million +23.2%2.9%4.6 $30.73
6/30/20238,840,000 shares $271.74 million +1.1%2.4%3.9 $30.74
6/15/20238,740,000 shares $281.43 million +15.3%2.3%4 $32.20
5/31/20237,580,000 shares $248.17 million +5.6%2.0%3.7 $32.74
5/15/20237,180,000 shares $246.49 million -7.4%1.9%3.7 $34.33
4/30/20237,750,000 shares $272.41 million +1.7%2.1%4.1 $35.15
4/15/20237,620,000 shares $276.30 million +0.9%2.1%4.1 $36.26
3/31/20237,550,000 shares $272.03 million -1.2%2.0%4 $36.03
3/15/20237,640,000 shares $263.58 million +3.7%2.1%4.2 $34.50
2/28/20237,370,000 shares $264.21 million +7.1%2.0%4.5 $35.85
2/15/20236,880,000 shares $259.31 million +8.2%1.9%4.4 $37.69
1/31/20236,360,000 shares $249.25 million -10.4%1.7%4.2 $39.19
1/15/20237,100,000 shares $279.53 million -9.0%1.9%4.8 $39.37
12/30/20227,800,000 shares $308.26 million +4.4%2.1%5.3 $39.52
12/15/20227,470,000 shares $304.70 million -2.9%2.0%4.9 $40.79
11/30/20227,690,000 shares $338.13 million +35.6%2.1%4.7 $43.97
Iran War Shock: What I Was Told In That Private Meeting (Ad)

You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel

Because THIS is the real reason.
11/15/20225,670,000 shares $238.59 million -14.7%1.6%3.4 $42.08
10/31/20226,650,000 shares $281.43 million -22.1%1.8%4.1 $42.32
10/15/20228,540,000 shares $353.64 million -0.5%2.4%5 $41.41
9/30/20228,580,000 shares $344.74 million -5.3%2.4%4.6 $40.18
9/15/20229,060,000 shares $382.06 million -9.9%2.5%4.6 $42.17
8/31/202210,050,000 shares $420.19 million -17.3%2.8%5.2 $41.81
8/15/202212,150,000 shares $533.75 million -10.0%3.3%6.2 $43.93
7/31/202213,500,000 shares $587.12 million +0.5%3.7%6.4 $43.49
7/15/202213,430,000 shares $589.98 million +0.8%3.7%6.2 $43.93
6/30/202213,330,000 shares $560.39 million -2.9%3.7%5.7 $42.04
6/15/202213,730,000 shares $529.02 million +35.9%3.8%5.7 $38.53
5/31/202210,100,000 shares $415.51 million +21.0%2.8%4.7 $41.14
5/15/20228,350,000 shares $333.50 million +13.5%2.3%4 $39.94
4/30/20227,360,000 shares $313.39 million -10.1%2.0%3.8 $42.58
4/15/20228,190,000 shares $361.18 million +17.5%2.3%4.4 $44.10
3/31/20226,970,000 shares $271.55 million +11.3%1.9%4.1 $38.96
3/15/20226,260,000 shares $239.57 million +4.5%1.7%4.1 $38.27
2/28/20225,990,000 shares $235.17 million +7.2%1.7%3.7 $39.26
2/15/20225,590,000 shares $225.50 million -7.3%1.6%3 $40.34
1/31/20226,030,000 shares $241.26 million -4.3%1.7%2.9 $40.01
1/15/20226,300,000 shares $249.86 million +7.7%1.8%2.9 $39.66
12/31/20215,850,000 shares $233.12 million -17.7%1.6%2.8 $39.85
12/15/20217,110,000 shares $266.77 million +20.3%2.0%3.5 $37.52
11/30/20215,910,000 shares $235.04 million -10.1%1.7%2.4 $39.77
11/15/20216,570,000 shares $273.97 million -17.6%1.9%2.8 $41.70
10/29/20217,970,000 shares $315.05 million +2.1%2.4%3.7 $39.53
10/15/20217,810,000 shares $299.83 million -7.4%2.3%3.3 $38.39
9/30/20218,430,000 shares $304.66 million +40.3%2.5%3.5 $36.14
9/15/20216,010,000 shares $228.20 million +2.2%1.8%2.4 $37.97

RPRX Short Interest - Frequently Asked Questions

Short interest is the volume of Royalty Pharma shares that have been sold short but have not yet been covered or closed out. As of August 14th, traders have sold 11,606,728 shares of RPRX short. 2.49% of Royalty Pharma's shares are currently sold short. Learn More on Royalty Pharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RPRX shares currently have a short interest ratio of 3.8. Learn More on Royalty Pharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.49% of Royalty Pharma's floating shares are currently sold short.

Royalty Pharma saw a increase in short interest in August. As of August 14th, there was short interest totaling 11,606,728 shares, an increase of 8.8% from the previous total of 10,667,818 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

2.49% of Royalty Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Royalty Pharma: Bristol Myers Squibb Company (2.25%), Sanofi (0.30%), GSK PLC Sponsored ADR (0.81%), Takeda Pharmaceutical Co. (0.09%), Teva Pharmaceutical Industries Ltd. (3.08%), BeOne Medicines Ltd. - Sponsored ADR (1.24%), Zoetis Inc. (4.07%), Viatris Inc. (3.23%), Jazz Pharmaceuticals PLC (5.81%), Neurocrine Biosciences, Inc. (4.69%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($71.57 billion), Invesco QQQ ($46.97 billion), iShares Russell 2000 ETF ($24.02 billion), Nebius Group N.V. ($15.37 billion), Sandisk Corporation ($12.60 billion), SPDR S&P Biotech ETF ($12.14 billion), Western Digital Corporation ($10.32 billion), iShares 20+ Year Treasury Bond ETF ($8.38 billion), VanEck Semiconductor ETF ($7.62 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($7.07 billion). View all of the most shorted stocks.

Short selling RPRX is an investing strategy that aims to generate trading profit from Royalty Pharma as its price is falling. RPRX shares are trading up $0.79 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Royalty Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RPRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RPRX, twice per month. The most recent reporting period available is August, 14 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like RPRX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:RPRX is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/25/2026. FINRA publishes updated short interest twice a month.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel